Severe	severe	O	O	O	O
complications	complications	O	O	O	O
of	of	O	O	O	O
antianginal	antianginal	O	O	O	O
drug	drug	O	O	O	O
therapy	therapy	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
patient	patient	O	O	O	O
identified	identified	O	O	O	O
as	as	O	O	O	O
a	a	O	O	O	O
poor	poor	O	O	O	O
metabolizer	metabolizer	O	O	O	O
of	of	O	O	O	O
metoprolol	metoprolol	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
propafenone	propafenone	O	O	OTHERS	I
,	,	O	O	O	O
diltiazem	diltiazem	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
sparteine	sparteine	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

A	a	O	O	O	O
47-year-old	47-year-old	O	O	O	O
patient	patient	O	O	O	O
suffering	suffering	O	O	O	O
from	from	O	O	O	O
coronary	coronary	O	DISEASE	OTHERS	I
artery	artery	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
was	was	O	O	O	O
admitted	admitted	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
CCU	ccu	O	O	O	O
in	in	O	O	O	O
shock	shock	O	DISEASE	OTHERS	I
with	with	O	O	O	O
III	iii	O	O	O	O
.	.	O	O	O	O

AV	av	O	DISEASE	OTHERS	I
block	block	O	DISEASE	OTHERS	I
,	,	O	O	O	O
severe	severe	O	O	O	O
hypotension	hypotension	O	DISEASE	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
impairment	impairment	O	O	OTHERS	I
of	of	O	O	OTHERS	I
ventricular	ventricular	O	O	OTHERS	I
function	function	O	O	OTHERS	I
.	.	O	O	O	O

One	one	O	O	O	O
week	week	O	O	O	O
prior	prior	O	O	O	O
to	to	O	O	O	O
admission	admission	O	O	O	O
a	a	O	O	O	O
therapy	therapy	O	O	O	O
with	with	O	O	O	O
standard	standard	O	O	O	O
doses	doses	O	O	O	O
of	of	O	O	O	O
metoprolol	metoprolol	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
100	100	O	O	O	O
mg	mg	O	O	OTHERS	I
t.i.d	t.i.d	O	O	O	O
.	.	O	O	O	O
and	and	O	O	O	O
then	then	O	O	O	O
100	100	O	O	O	O
mg	mg	O	O	OTHERS	I
b.i.d	b.i.d	O	O	O	O
.	.	O	O	O	O
)	)	O	O	O	O
had	had	O	O	O	O
been	been	O	O	O	O
initiated	initiated	O	O	O	O
.	.	O	O	O	O

Two	two	O	O	O	O
days	days	O	O	O	O
before	before	O	O	O	O
admission	admission	O	O	O	O
diltiazem	diltiazem	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
60	60	O	O	O	O
mg	mg	O	O	OTHERS	I
b.i.d	b.i.d	O	O	O	O
.	.	O	O	O	O
)	)	O	O	O	O
was	was	O	O	O	O
prescribed	prescribed	O	O	O	O
in	in	O	O	O	O
addition	addition	O	O	O	O
.	.	O	O	O	O

Analyses	analyses	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
blood	blood	O	O	O	O
sample	sample	O	O	O	O
revealed	revealed	O	O	O	O
unusually	unusually	O	O	O	O
high	high	O	O	O	O
plasma	plasma	O	O	O	O
concentrations	concentrations	O	O	O	O
of	of	O	O	O	O
metoprolol	metoprolol	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
greater	greater	O	O	O	O
than	than	O	O	O	O
3000	3000	O	O	O	O
ng/ml	ng/ml	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
diltiazem	diltiazem	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
526	526	O	O	O	O
ng/ml	ng/ml	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
patient	patient	O	O	O	O
recovered	recovered	O	O	O	O
within	within	O	O	O	O
1	1	O	O	O	O
week	week	O	O	O	O
following	following	O	O	O	O
discontinuation	discontinuation	O	O	O	O
of	of	O	O	O	O
antianginal	antianginal	O	O	O	O
therapy	therapy	O	O	O	O
.	.	O	O	O	O

Three	three	O	O	O	O
months	months	O	O	O	O
later	later	O	O	O	O
the	the	O	O	O	O
patient	patient	O	O	O	O
was	was	O	O	O	O
exposed	exposed	O	O	O	O
to	to	O	O	O	O
a	a	O	O	O	O
single	single	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
metoprolol	metoprolol	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
diltiazem	diltiazem	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
propafenone	propafenone	O	O	OTHERS	I
(	(	O	O	O	O
since	since	O	O	O	O
he	he	O	O	O	O
had	had	O	O	O	O
received	received	O	O	O	O
this	this	O	O	O	O
drug	drug	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
past	past	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
sparteine	sparteine	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
as	as	O	O	O	O
a	a	O	O	O	O
probe	probe	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
debrisoquine/sparteine	debrisoquine/sparteine	O	O	O	O
type	type	O	O	O	O
polymorphism	polymorphism	O	O	O	O
of	of	O	O	O	O
oxidative	oxidative	O	O	O	O
drug	drug	O	O	O	O
metabolism	metabolism	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

It	it	O	O	O	O
was	was	O	O	O	O
found	found	O	O	O	O
that	that	O	O	O	O
he	he	O	O	O	O
was	was	O	O	O	O
a	a	O	O	O	O
poor	poor	O	O	O	O
metabolizer	metabolizer	O	O	O	O
of	of	O	O	O	O
all	all	O	O	O	O
four	four	O	O	O	O
drugs	drugs	O	O	O	O
,	,	O	O	O	O
indicating	indicating	O	O	O	O
that	that	O	O	O	O
their	their	O	O	O	O
metabolism	metabolism	O	O	O	O
is	is	O	O	O	O
under	under	O	O	O	O
the	the	O	O	O	O
same	same	O	O	O	O
genetic	genetic	O	O	O	O
control	control	O	O	O	O
.	.	O	O	O	O

Therefore	therefore	O	O	O	O
,	,	O	O	O	O
patients	patients	O	O	O	O
belonging	belonging	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
poor-metabolizer	poor-metabolizer	O	O	O	O
phenotype	phenotype	O	O	O	O
of	of	O	O	O	O
sparteine/debrisoquine	sparteine/debrisoquine	O	O	O	O
polymorphism	polymorphism	O	O	O	O
in	in	O	O	O	O
drug	drug	O	O	O	O
metabolism	metabolism	O	O	O	O
,	,	O	O	O	O
which	which	O	O	O	O
constitutes	constitutes	O	O	O	O
6.4	6.4	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
German	german	O	O	O	O
population	population	O	O	O	O
,	,	O	O	O	O
may	may	O	O	O	O
experience	experience	O	O	O	O
adverse	adverse	O	O	OTHERS	I
drug	drug	O	O	OTHERS	I
reactions	reactions	O	O	OTHERS	I
when	when	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
standard	standard	O	O	O	O
doses	doses	O	O	O	O
of	of	O	O	O	O
one	one	O	O	O	O
of	of	O	O	O	O
these	these	O	O	O	O
drugs	drugs	O	O	O	O
alone	alone	O	O	O	O
.	.	O	O	O	O

Moreover	moreover	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
coadministration	coadministration	O	O	O	O
of	of	O	O	O	O
these	these	O	O	O	O
frequently	frequently	O	O	O	O
used	used	O	O	O	O
drugs	drugs	O	O	O	O
is	is	O	O	O	O
expected	expected	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
especially	especially	O	O	O	O
harmful	harmful	O	O	O	O
in	in	O	O	O	O
this	this	O	O	O	O
subgroup	subgroup	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

